MTOR and breast cancer: Given that NVP-BEZ235 is a poor inhibitor of AKT and PDK1 [20, 21], and inhibition of mTOR by AZD8055 prevents the activation of both AKT-T308 and AKT-S473 [9], in our model AZD8055 is a better treatment for breast cancer.